Portal de Periódicos da CAPES

Calcineurin Inhibitors in the Treatment of Adult Autoimmune Hepatitis: A Systematic Review

2022; Volume: 000; Issue: 000 Linguagem: Inglês

10.14218/jcth.2021.00535

2310-8819

Martine Baven-Pronk, Joffre M. Hew, Maaike Biewenga, Maarten E. Tushuizen, Aad P. van den Berg, Gerd Bouma, Johannes T. Brouwer, Bart van Hoek,

Pediatric Hepatobiliary Diseases and Treatments

Background and AimsA considerable number of autoimmune hepatitis (AIH) patients completely or partially fail on first-line treatment. Several studies on the use of calcineurin inhibitors (CNIs) in the treatment of AIH have been published without focusing on indication. The aim was to assess the efficacy of CNIs in the treatment of adult AIH patients, specifically focusing on indication: first-line intolerant and with first-line insufficient response (failure to achieve or maintain remission), and with second versus third-line treatment.